Clinical Scorecard: Enhancing Motor Function via Modulation of Perineuronal Nets in a Mouse Model of Parkinson’s Disease
At a Glance
Category
Detail
Condition
Parkinson’s disease with motor deficits
Key Mechanisms
Perineuronal nets (PNNs) around parvalbumin interneurons regulate plasticity; transient PNN removal via chondroitinase ABC (ChABC) modulates motor cortex plasticity and function
Preclinical research and potential future therapeutic strategies for motor rehabilitation
Key Highlights
Transient reduction of primary motor cortex PNNs by ChABC in healthy adult mice causes temporary motor deficits.
6-OHDA lesions reduce PNN levels bilaterally in primary motor cortex transiently, returning to baseline by 5 weeks post-lesion.
ChABC treatment combined with motor stimulation in lesioned mice promotes motor recovery associated with increased PNN-enwrapped parvalbumin interneurons and synaptic rebalancing.
Guideline-Based Recommendations
Diagnosis
Use unilateral 6-OHDA lesions in mice to model Parkinson’s disease motor deficits.
Assess PNN levels in primary motor cortex as markers of plasticity state post-lesion.
Management
Apply local ChABC injections to transiently degrade PNNs in primary motor cortex.
Combine PNN removal with motor stimulation to enhance motor recovery in PD models.
Monitoring & Follow-up
Monitor motor function changes following PNN modulation.
Track PNN levels and parvalbumin interneuron markers to evaluate plasticity and recovery.
Risks
Transient PNN removal in healthy cortex may induce temporary motor deficits.
ChABC effects are transient and require coupling with motor stimulation for functional benefit.
Patient & Prescribing Data
Adult mice with Parkinsonian motor deficits induced by 6-OHDA lesions
ChABC-mediated PNN removal alone does not improve motor function; combined with motor stimulation, it facilitates motor recovery by enhancing cortical plasticity.
Clinical Best Practices
Target PNNs in the primary motor cortex to modulate plasticity for motor rehabilitation.
Use transient enzymatic degradation of PNNs with ChABC to unlock plasticity windows.
Pair PNN modulation with active motor training to maximize functional recovery.
Consider timing of interventions relative to lesion-induced PNN plasticity phases.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
